Advanced melanoma: New targeted therapy successful in more than 80 percent of patients

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas, appear in a new study.

Read the whole article on Science Daily

More from Science Daily